ClinicalTrials.Veeva

Menu
C

Chrysalis Clinical Research | St. George, UT

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

RO7795081
LY3502970
Orforglipron
Survodutide
Insulin icodec
Pseudoephedrine
LY3298176
Maridebart Cafraglutide
Tirzepatide
CT-388

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 11 total trials
Locations recently updated

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tol...

Enrolling
Obesity or Overweight
Drug: RO7795081
Drug: Placebo

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of CT-388...

Active, not recruiting
Overweight
Obesity
Drug: CT-388
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Active, not recruiting
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Active, not recruiting
Obesity
Drug: Retatrutide
Drug: Tirzepatide

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study...

Enrolling
Type 2 Diabetes Mellitus
Drug: Semaglutide
Drug: Placebo

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting
Obesity
Drug: Placebo
Drug: survodutide

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The pri...

Enrolling
Weight Management
Drug: GV101 placebo
Drug: GV101

Trial sponsors

Lilly logo
Novo Nordisk logo
Roche logo
Amgen logo
Boehringer Ingelheim logo
C
G
Perrigo logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems